New Alzheimer's drug under close watch: can lecanemab slow memory loss?
NCT ID NCT06741553
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study follows 120 people with early Alzheimer's or mild cognitive impairment who are taking lecanemab, an FDA-approved drug that targets amyloid plaques in the brain. Researchers will track changes in memory, daily function, and brain scans over 18 months to see if the drug slows decline. They will also watch for side effects like brain swelling or small bleeds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lecanemab
What this could lead to
If successful, this could confirm that lecanemab slows cognitive decline in early Alzheimer's, offering a disease-modifying option for patients.
What could go wrong
This is an observational follow-up, not a new treatment test. Lecanemab can cause brain swelling or microbleeds (ARIA), and benefits may be modest.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital, School of Medicine, Zhejiang University, China
RECRUITINGHangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••